Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery

Annals of Surgical Oncology

Volumn 19, Issue 3, 2012, Pages 817-825

  Zhu, Cheng Bao ^a   Chen, Li Li ^b   Tian, Jian Jun ^a   Su, Liang ^a   Wang, Can ^a   Gai, Zhong Tao ^a   Du, Wen Jun ^a   Guo Liang, Ma ^c  

^a SHANDONG UNIVERSITY   (China)

^b Second People's Hospital of Jinan   (China)

^c Affiliated Laiwu Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; LECTIN; PROTEIN YKL 40; TUMOR MARKER; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; ADOLESCENT; BLOOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADIPOKINES; ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LECTINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862266584     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2026-3     Document Type: Article

References (43)

1. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127:218-24.
2. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107-16. (Pubitemid 43361543)
3. Maheshwari S, Sarraj A, Kramer J, et al. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506-13. (Pubitemid 47331743)
4. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem.1993;268:25803-10. (Pubitemid 23358198)
5. De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (Cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285:926-31. (Pubitemid 32918025)
6. Malinda KM, Ponce L, Kleinman HK, et al. Gp38 k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999;250:168-73. (Pubitemid 29391580)
7. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology. 1999;38:618-26. (Pubitemid 29507329)
8. Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32:911-20. (Pubitemid 30368084)
9. Nordenbaek C, Johansen JS, Junker P, et al. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis. 1999;180:1722-6. (Pubitemid 29506483)
10. Cintin C, Johansen JS, Christensen IJ, et al. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002;95(2):267-74. (Pubitemid 34787591)
11. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat. 2003;80: 15-21. (Pubitemid 36851281)
12. Dehn H, Høgdall EVS, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand. 2003;82:287-93. (Pubitemid 36459738)
13. Thöm I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114-21.
14. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503-13.
15. Geertsen P, Johansen JS, von der Maase H, et al. High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with highdose continuous intravenous infusion of interleukin-2. Proc Am Soc Clin Oncol. 2003;22:abstract1603.
16. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698-704. (Pubitemid 44629598)
17. Schmidt H, Johansen JS, Gehl J, et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-9.
18. Roslind A, Johansen JS, Christensen IJ, et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-63.
19. Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435-42. (Pubitemid 46156955)
20. Shackel NA, McGuinness PH, Abbott CA, et al. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology. 2003;38:577-588. (Pubitemid 37052145)
21. Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene. 2006;25: 1242-50.
22. Ringsholt M, Høgdall EV, Johansen JS, et al. YKL-40 protein expression in normal adult human tissues-an immunohistochemical study. J Mol Histol. 2007;38:33-43. (Pubitemid 46422155)
23. Johansen JS, Bojesen SE, Mylin AK, et al. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27:572-8.
24. Schepke M, Roth F, Fimmers R, et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol. 2003;98:1167-74. (Pubitemid 36733783)
25. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
26. Varotti G, Ramacciato G, Ercolani G, et al. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol. 2005;31:760-7. (Pubitemid 41194654)
27. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol. 1996;35:553-9.
28. Royston P. Constructing time-specific reference ranges. Stat Med. 1991;10:675-90.
29. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196;254-65. (Pubitemid 34189413)
30. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90:2053-8. (Pubitemid 38869704)
31. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-8. (Pubitemid 38082155)
32. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Phys.1998;110:351-60. (Pubitemid 28345905)
33. Renkema GH, Boot RG, Au FL, et al: chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitinbinding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504-9. (Pubitemid 28080953)
34. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221-5. (Pubitemid 27335226)
35. Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058-67. (Pubitemid 37377146)
36. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194-202. (Pubitemid 43342164)
37. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9:4423-34. (Pubitemid 37248400)
38. Schmidt H, Johansen JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24:798-804. (Pubitemid 46622047)
39. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol N Y. 2011;7:16-24.
40. Liu P, Yang JM, Niu WY, et al. Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol. 2010;16:1123-8.
41. Ikegami T, Ezaki T, Ishida T, et al. Limited hepatic resection for hepatocellular carcinoma in the caudate lobe. World J Surg. 2004;28:697-701. (Pubitemid 39097128)
42. Johansen JS, Brasso K, Iversen P, et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res. 2007;13:3244-9. (Pubitemid 46944908)
43. Shirabe K, Wakiyama S, Gion T, et al. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma-results of 152 resected cases. Hepatogastroenterology. 2007;54:2084-7.